I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
The Southern Nevada Health District announced Wednesday that it will start hosting free diabetes self-management, education, ...
There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...
Getting to know what’s going on in your body can help you manage type 2 diabetes well. It’s a chronic condition in which your body doesn’t use insulin properly. This causes sugar to build up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback